Subcommittee E56.08 on Nano-Enabled Medical Products | ASTM

Using Artificial Intelligence (AI) on ASTM standards and related intellectual property is prohibited. Violations will result in suspension of access.

Home
FAQ

Home
FAQ

Home
Membership & Participati…

/

Technical Committees

/

Subcommittee E56.08 on N…

Subcommittee E56.08 on Nano-Enabled Medical Products

Loading...

About ASTM

Governance Global Cooperation Corporate Citizenship History Regional Offices and Websites Diversity, Equity, Inclusion & Belonging Culture & Careers

Membership & Participation

Membership Technical Committees Member Tools Meetings, Symposia & Workshops Academic Outreach Emerging Professionals Publish with ASTM Consumer Participation

Standards & Solutions

Standards & Publications Enterprise Solutions ASTM Compass®Digital Library Market Insights & Innovation Laboratory Services Training Courses Certification Cement & Concrete Reference Lab

News

Standardization News Press Releases Podcasts Español Editorial Calendar and Media Kit

Help

Contact ASTM Locations FAQ

Policies

Privacy Policy Logo Policy IP Policy Return Policy Copyright & Permissions

Copyright © 1996 - 2025 ASTM. All Rights Reserved. ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA, 19428-2959 USA

Matching Standards Under the Jurisdiction of E56.08 by Status

E3238-20 Standard Test Method for Quantitative Measurement of the Chemoattractant Capacity of a Nanoparticulate Material in vitro
E3275-21 Standard Guide for Visualization and Identification of Nanomaterials in Biological and Nonbiological Matrices Using Darkfield Microscopy/Hyperspectral Imaging (DFM/HSI) Analysis
E3297-21 Standard Test Method for Lipid Quantitation in Liposomal Formulations Using High Performance Liquid Chromatography (HPLC) with a Charged Aerosol Detector (CAD)
-See also WK85364 proposed Revision
E3323-22 Standard Test Method for Lipid Quantitation in Liposomal Formulations Using High Performance Liquid Chromatography (HPLC) with an Evaporative Light-Scattering Detector (ELSD)
-See also WK85365 proposed Revision
E3324-22 Standard Test Method for Lipid Quantitation in Liposomal Formulations Using Ultra-High-Performance Liquid Chromatography (UHPLC) with Triple Quadrupole Mass Spectrometry (TQMS)
-See also WK85363 proposed Revision
E3351-22 Standard Test Method for Detection of Nitric Oxide Production In Vitro
E3482-25 Standard Guide for Characterization of Encapsulation, Extraction, and Analysis of RNA in Lipid Nanoparticle Formulations for Drug Delivery
E3483-25 Standard Test Method for Evaluating the Impact of Nanomaterials on Phagocytic Function in Vitro

WK69051 Assessing the Activation of the Complement System in Human Plasma Through Quantification of iC3b Concentration by ELISA,
WK67980 Quantifying Poly(ethylene glycol) Coating on the Surface of Gold Nanostructured Materials Using High Performance Liquid Chromatography with Evaporative Light Scattering Detection (HPLC/ELSD)
WK86057 New Standard Test Method for Measuring Sulfate and Ammonium Ion Concentrations in Liposome Drug Formulations
WK86056 Measuring In Vitro Drug Release from Liposomal Drug Formulations.